The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …

Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in
onset and progression of the condition would significantly reduce the global burden of the …

… ’s dementia has been clinically established and the progressing cognitive deficits affect the
patient’s … among other things on the patient’s premorbid cognitive and intellectual level and is …

Cerebral small vessel disease (SVD) is a common accompaniment of ageing. Features
seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter …

Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's
disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a …

Objective: Active or passive immunisation can mitigate plaque pathology in murine models
of Alzheimer’s disease (AD). Recently, it has been shown that antibodies against β-amyloid (…

Background Abnormal hyperphosphorylation of the microtubule-associated protein tau and
its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of …

Alzheimer's disease (AD) is characterized by a heterogeneous distribution of pathological
changes throughout the brain. Magnetic resonance imaging can be used to investigate the …

… Teipel S, Grothe MJ. Does posterior cingulate hypometabolism result from disconnection
or local pathology across preclinical and clinical stages of Alzheimer's disease? Eur J Nucl …

Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical
Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal …